Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Novartis and Legend Biotech Sign Exclusive License Agreemen

<< Previous

Bullboard Posts

Next >>

Comment by Buckhenryon Nov 16, 2023 3:15pm

107 Views

Post# 35739839

RE:RE:RE:RE:RE: Novartis and Legend Biotech Sign Exclusive License Agreemen

Many companies have died on the vine because they did not understand and have the right folks to bring a product to market. You may have the best widget in the world but it's worthless if you don't know how to bring it to Market

<< Previous

Bullboard Posts

Next >>

The top 10 artificial intelligence penny stocks